GlobeNewswire Inc.··Theriva BiologicsTheriva Biologics Advances VCN-01 Pancreatic Cancer Program With Phase 3 FDA Approval
Theriva Biologics will present expanded VIRAGE trial data for VCN-01 at AACR 2026, with FDA and EMA agreement on Phase 3 design for metastatic pancreatic cancer treatment.
TOVXFDA approvalPhase 3 trial